核心观点三生制药公布2024 年年报，全年营业收入91.08 亿元，同比增长17.45%，经调整的经营性归母净利润23.2 亿元，同比增长18.8%，符合市场预期。核心产品特比澳营收50.6 亿元，同比增长20.4%，今年有望继续保持稳健增长。公司未来将继续聚焦创新药物开发，重点布局是在肿瘤、自免、肾科等广泛患者需求的领域。2025 年重点关注：（1）PD-1/VEGF（707）双抗临床2 期数据...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.